Notes to Consolidated Financial Statements (Unaudited)
NOTE 1 – BASIS OF PRESENTATION
The accompanying unaudited consolidated financials statements of WindGen Energy, Inc. (formerly InMedica Development Corporation) and its majority owned subsidiary, MicroCor, Inc. (collectively the “Company”) have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company generated a net loss of $95,232 and $27,217 for the three month periods ended March 31, 2010 and 2009, respectively, and negative cash flows from operations of $95,715 and $577 for the three month periods ended March 31, 2010 and 2009, respectively. As of March 31, 2010, the Company had an accumulated deficit of $9,432,058. At March 31, 2010, the Company had a stockholders’ deficit of $512,607. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. The Company’s continued existence is dependent upon its ability to execute its operating plan and to obtain additional debt or equity financing. There can be no assurance that the necessary debt or equity financing will be available, or will be available on terms acceptable to the Company.
The accompanying consolidated financial statements of the Company are unaudited. However, in management’s opinion, all adjustments, consisting only of normal recurring adjustments necessary for fair presentation of results for the interim periods shown, have been made. Results for interim periods are not necessarily indicative of those to be expected for the full year. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2009.
NOTE 2 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
On April 17, 2009, the Company entered into a license agreement (the “License”) with Wind Sail Receptor, Inc. of Boulder City, Nevada (“WSR”), pursuant to which the Company was granted the exclusive license to sell WSR’s wind sail receptor wind generation systems using blades of 15 feet in length or less in the United States, Canada, the United Kingdom and Ireland, with nonexclusive rights in the rest of the world except Latin America and the Caribbean. Under the License, the Company must acquire 100 blades from WSR during the year after WSR is able to manufacture the receptors. WSR is hopeful of commencing manufacture of the blades in the second half of 2010. The Company will market WSR’s wind receptor blades through its new division called WindGen Energy. The Company is currently negotiating with WSR to add additional exclusive territory to the License and, in addition, amending the License to allow the Company to manufacture and/or assemble the WSR wind generation systems.
On December 4, 2009, the Company changed its name to WindGen Energy, Inc.
On December 4, 2009, the Company increased its authorized capital to 100,000,000 shares of common stock.
(Formerly InMedica Development Corporation)
Notes to Consolidated Financial Statements (Unaudited)
NOTE 2 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Principles of Consolidation
The consolidated financial statements include the accounts of WindGen and MicroCor. All material inter-company accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Patents
The Company has three patents covering various aspects of its hematocrit technology, which expire from 2010 to 2013.
Research and Development
Research and development costs are expensed as incurred.
Net Loss Per Common Share
Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the year. Diluted net loss per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other common stock equivalents were exercised or converted into common stock. At March 31, 2010 and December 31, 2009, respectively, there were 31,524 and 31,524 potentially dilutive common stock equivalents. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net loss per common share.
(Formerly InMedica Development Corporation)
Notes to Consolidated Financial Statements (Unaudited)
NOTE 3 – PREFERRED STOCK
The Company is authorized to issue 100,000,000 shares of preferred stock. The Company’s board of directors designated 1,000,000 shares of this preferred stock as Series A Cumulative Convertible Preferred Stock (“Series A Preferred”) with a par value of $4.50 per share. Holders of the Series A Preferred receive annual cumulative dividends of eight percent, payable quarterly, which dividends are required to be fully paid or set aside before any other dividend on any class or series of stock of the Company is paid. As of March 31, 2010, cumulative preferred stock dividends are due and payable in the amount of $66,200. Holders of the Series A Preferred receive no voting rights but do receive a liquidation preference of $4.50 per share, plus accrued and unp aid dividends. Series A Preferred stockholders have the right to convert each share of Series A Preferred to the Company’s common stock at a rate of 1.5 common shares to 1 preferred share.
On January 30, 2009, the Company entered into an agreement with MicroCor, its subsidiary (the “MicroCor Agreement”). The MicroCor Agreement provides for the Company to create a Series B class of preferred stock, without dividend or voting rights (the “Series B Preferred”), which will receive 100% of any future benefit from the sale, spin-off, merger or liquidation of MicroCor or the commercialization of its hematocrit technology. The shares of the Series B Preferred will be distributed as a dividend, subject to compliance with federal and state securities laws and regulations, to the Company’s common stockholders, as of January 30, 2009. The creation of the Series B Preferred will prevent any holder of the Company’s common stock after January 30, 200 9 from sharing in any future benefit of or to MicroCor through the expiration date of January 30, 2011.
NOTE 4 - COMMON STOCK TRANSACTIONS
During the first quarter ending March 31, 2010, the Company issued 1,866,667 shares of common stock for cash of $140,000. The stock issuances were the result of a private placement offering commenced January 20, 2010 for a total offering of $300,000. The Private Placement is still being offered until June 30, 2010, at which time the Company may elect to continue the offering for an additional six months.
On December 4, 2009, the Company changed its total authorized common shares from 40,000,000 to 100,000,000 shares.
(Formerly InMedica Development Corporation)
Notes to Consolidated Financial Statements (Unaudited)
NOTE 5 – EARNINGS PER SHARE
The following data show the amounts used in computing earnings per share and the effect on income and the weighted average number of shares of dilutive potential common stock:
| | For the Quarters Ended | |
| | March 31, | |
| | 2010 | | | 2009 | |
| | | | | | |
Net Income (Loss) | | $ | 97,123 | | | $ | 29,108 | |
Less: preferred dividends | | | (1,891 | ) | | | (1,891 | ) |
| | | | | | | | |
Income (Loss) available to common stockholders used in basic EPS | | $ | 95,232 | | | $ | 27,217 | |
| | | | | | | | |
Convertible preferred stock | | | 1,891 | | | | 1,891 | |
Convertible notes payable | | | – | | | | – | |
Income (Loss) available to common stockholders after assumed | | | | | | | | |
conversion of dilutive securities | | $ | 97,123 | | | $ | 29,108 | |
| | | | | | | | |
Weighted average number of common shares used in basic EPS | | | 34,921,344 | | | | 18,629,493 | |
Effect of dilutive securities: | | | | | | | | |
Convertible preferred stock | | | 31,524 | | | | 31,524 | |
Convertible notes payable | | | – | | | | – | |
Options | | | – | | | | 20,000,000 | |
Weighted average number of common shares and dilutive potential | | | | | | | | |
common stock used in diluted EPS | | | 34,952,868 | | | | 38,661,017 | |